Accessibility Menu
Molecular Pharmacology (usa) logo

Molecular Pharmacology (usa)(OTC) MLPH

Market Cap$643.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year+544%
1 Year+64,300%
1 Month+59%
$0.03
+0.00%
+0.00Today
Molecular Pharmacology (usa) last closing stock price
MetricPriceDate
Last closeUSD 0.032026-08-03
Molecular Pharmacology (usa) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+59.41%USD 0.022026-07-14
1 month+59.41%USD 0.022026-07-01
3 month+222%USD 0.012026-04-30
Year to date+61%USD 0.022025-12-29
1 year+64,300%USD 0.002025-07-08
3 year+61%USD 0.022023-08-04
5 year+544%USD 0.012021-06-25
Since inception-99.83%USD 19.502006-05-09

Molecular Pharmacology (usa) Financials at a Glance

Market Cap

$643.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$6.72K

EPS (TTM)

-$0.00

P/E Ratio

-64.40

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.03

Volume

431

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.03 - $0.49

Estimated Earnings Date

N/A

MLPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Molecular Pharmacology (usa)

Molecular Pharmacology (USA), Ltd. is a development-stage biotechnology company focused on creating innovative solutions for pain and inflammation. The company primarily targets the Australian and United States markets with its lead product, Tripeptofen, an analgesic and anti-inflammatory molecule.

Products and Services
  • Tripeptofen, designed to alleviate common daily pain
  • Diverse dosage forms and formulations to meet various needs
  • Collaborative therapeutic and cosmetic products through partnerships
Growth Outlook
  • Focus on expanding market presence in the U.S. and Australia
  • Partnerships with pharmaceutical distributors enhance distribution capabilities
  • Development of a suite of therapeutic products with Dermatology Development Corporation
Financial Highlights
  • Recent quarterly net income of -$600 indicates ongoing investment in development
  • Trailing twelve months show consistent operating expenses, reflecting strategic growth
  • Market capitalization of approximately $403,819 suggests potential for future growth
Molecular Pharmacology (USA), Ltd. operates with a clear focus on addressing pain and inflammation through innovative solutions. The company’s flagship product, Tripeptofen, is positioned to meet the needs of patients seeking effective pain relief. With a strategic marketing approach that includes partnerships with pharmaceutical distributors, the company aims to enhance its market reach and product availability. The growth outlook for Molecular Pharmacology is promising, as the company continues to explore opportunities in both the U.S. and Australian markets. Collaborations with established entities, such as Dermatology Development Corporation, further strengthen its product offerings and market presence. Financially, the company is in a development phase, as indicated by its recent quarterly net income and consistent operating expenses. The current market capitalization reflects the potential for future growth as the company advances its product pipeline and expands its market footprint. Overall, Molecular Pharmacology (USA), Ltd. presents an intriguing opportunity for investors interested in the biotechnology sector focused on pain management solutions.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Xin Shi

Website

www.mpl-usa.com

Headquarters

Perth, WA 6007, AU

MLPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

-1.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$643.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.99M

Volume

431

Avg. Volume

393.563

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$6.72K

EBITDA

-$6.72K

Operating Cash Flow

-$109.35K

Capital Expenditure

$0.00

Free Cash Flow

-$109.35K

Cash & ST Invst.

$1.52K

Total Debt

$0.00

Molecular Pharmacology (usa) Performance Analysis

Molecular Pharmacology (usa) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Molecular Pharmacology (usa) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-30N/A
Q22024-12-31N/A
Q32025-03-31N/A
Q32026-03-31N/A
Molecular Pharmacology (usa) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00N/A
20232023-12-31USD -0.00-85.7%
20242024-12-31USD -0.000.0%
20252025-12-31USD -0.000.0%
Molecular Pharmacology (usa) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-30N/A
Q22024-12-31N/A
Q32025-03-31N/A
Q32026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$643.70KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$643.70K

N/A

Employees

1

N/A

Net Income

-$600.00

+44.7%

EBITDA

-$600.00

+44.7%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$1.52K

-78.8%

Total Debt

$0.00

N/A

Accounts Receivable

$7.33K

+35.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

-$32.28K

-13.9%

Operating Cash Flow

-$32.28K

-13.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NSPDFNaturally Splendid Enterprises Ltd.
$0.04+0.00%
BSSPBaseline Productions, Inc.
$0.00+0.00%
AFFYAffymax, Inc.
$0.00+0.00%
NUNZNunzia Pharmaceutical Company
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.27-0.14%
NVDANvidia
$219.22+0.03%
ONDSOndas
$8.87+0.00%
PATHUiPath
$13.82-0.02%

Questions About MLPH

What is the current price of Molecular Pharmacology (usa)?

Molecular Pharmacology (usa) is trading at $0.03 per share.

What is the 52-week range for Molecular Pharmacology (usa)?

Over the past 52 weeks, Molecular Pharmacology (usa) has traded between $0.03 and $0.49.

How much debt does Molecular Pharmacology (usa) have?

As of the most recent reporting period, Molecular Pharmacology (usa) reported total debt of $0.00.

How much cash does Molecular Pharmacology (usa) have on hand?

Molecular Pharmacology (usa) reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Molecular Pharmacology (usa)’s dividend yield?

Molecular Pharmacology (usa) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services